{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:27:09Z","timestamp":1786980429705,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00774-020-01158-2","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T12:03:58Z","timestamp":1602504238000},"page":"396-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of etelcalcetide on parathyroid hormone secretion by primary hyperparathyroidism patient-derived primary parathyroid cells"],"prefix":"10.1007","volume":"39","author":[{"given":"Aiko","family":"Fujioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikue","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutsune","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiyasu","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Miyaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"1158_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913\u2013921","journal-title":"Clin J Am Soc Nephrol"},{"key":"1158_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.18553\/jmcp.2007.13.5.397","volume":"13","author":"MS Joy","year":"2007","unstructured":"Joy MS, Karagiannis PC, Peyerl FW (2007) Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 13:397\u2013411","journal-title":"J Manag Care Pharm"},{"key":"1158_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627\u2013635","journal-title":"J Pharmacol Exp Ther"},{"key":"1158_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, Hunter T, Yin Q, Maclean D, Bell G, Mendel DB, Johnson RM, Karim F (2013) Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 346:229\u2013240","journal-title":"J Pharmacol Exp Ther"},{"key":"1158_CR5","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s40265-016-0671-3","volume":"76","author":"HA Blair","year":"2013","unstructured":"Blair HA (2013) Etelcalcetide: First global approval. Drugs 76:1787\u20131792","journal-title":"Drugs"},{"key":"1158_CR6","first-page":"537","volume":"27","author":"A Inoue","year":"2017","unstructured":"Inoue A, Harada K (2017) The discovery, research and development of etelcalcetide hydrochloride, the world 1st intravenous calcimimetics (in Japanese). Clin Calcium 27:537\u2013545","journal-title":"Clin Calcium"},{"key":"1158_CR7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1124\/mol.115.098392","volume":"88","author":"ST Alexander","year":"2015","unstructured":"Alexander ST, Hunter T, Walter S, Dong J, Maclean D, Baruch A, Subramanian R, Tomlinson JE (2015) Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol 88:853\u2013865","journal-title":"Mol Pharmacol"},{"key":"1158_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1254\/fpj.150.98","volume":"150","author":"K Harada","year":"2017","unstructured":"Harada K, Inoue A, Yamauchi A, Fujii A (2017) The pharmacological profile and the clinical efficacy of the world\u2019s 1st intravenous calcimimetics; etelcalcetide hydrochloride (Parsabiv\u00ae) (in Japanese). Nippon Yakurigaku Zasshi (Folia Pharmacol Jpn) 150:98\u2013113","journal-title":"Nippon Yakurigaku Zasshi (Folia Pharmacol Jpn)"},{"key":"1158_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejphar.2018.10.021","volume":"842","author":"K Harada","year":"2019","unstructured":"Harada K, Fujioka A, Konno M, Inoue A, Yamada H, Hirota Y (2019) Pharmacology of Parsabiv\u00ae (etelcalcetide, ONO-5163\/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients. Eur J Pharmacol 842:139\u2013145","journal-title":"Eur J Pharmacol"},{"key":"1158_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM (2017) Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 317:156\u2013164","journal-title":"JAMA"},{"key":"1158_CR11","first-page":"1723","volume":"32","author":"M Fukagawa","year":"2017","unstructured":"Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T, Odani M, Akizawa T, ONO-5163 Study Group (2017) A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32:1723\u20131730","journal-title":"Nephrol Dial Transplant"},{"key":"1158_CR12","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1210\/jc.2002-021370","volume":"87","author":"JP Bilezikian","year":"2002","unstructured":"Bilezikian JP, Potts JT Jr, Gel-H F, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA Jr (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 87:5353\u20135361","journal-title":"J Clin Endocrinol Metab"},{"key":"1158_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00774-006-0687-y","volume":"24","author":"T Kawata","year":"2006","unstructured":"Kawata T, Imanishi Y, Kobayashi K, Onoda N, Okuno S, Takemoto Y, Komo T, Tahara H, Wada M, Nagano N, Ishimura E, Miki T, Ishikawa T, Inaba M, Nishizawa Y (2006) Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 24:300\u2013306","journal-title":"J Bone Miner Metab"},{"key":"1158_CR14","unstructured":"Ono Pharmaceutical Co., Ltd., Etelcalcetide application dossier CTD 2.6.2.6. (in Japanese). https:\/\/www.pmda.go.jp\/drugs\/2016\/P20161220003\/index.html. 2016. Accessed 21 Apr 2020"},{"key":"1158_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1006\/bbrc.1995.2048","volume":"212","author":"AJ Brown","year":"1995","unstructured":"Brown AJ, Zhong M, Ritter C, Brown EM, Slatoptlsky E (1995) Loss of calcium responsiveness in cultured bovine parathyroid cells is associated with decreased calcium receptor expression. Biochem Biophys Res Commun 212:861\u2013867","journal-title":"Biochem Biophys Res Commun"},{"key":"1158_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/1744-9987.12352","volume":"20","author":"Y Tominaga","year":"2016","unstructured":"Tominaga Y, Kakuta T, Yasunaga C, Nakamura M, Kadokura Y, Tahara H (2016) Evaluation of parathyroidectomy for secondary and tertiary hyperparathyroidism by the Parathyroid Surgeons\u2019 Society of Japan. Ther Apher Dial 20:6\u201311","journal-title":"Ther Apher Dial"},{"key":"1158_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1517\/17460440903022743","volume":"4","author":"Y Imanishi","year":"2009","unstructured":"Imanishi Y, Inaba M, Kawata T, Nishizawa Y (2009) Animal models of hyperfunctioning parathyroid diseases for drug development. Expert Opin Drug Discov 4:727\u2013740","journal-title":"Expert Opin Drug Discov"},{"key":"1158_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.ekir.2019.04.010","volume":"4","author":"J Cunningham","year":"2019","unstructured":"Cunningham J, Block GA, Chertow GM, Cooper K, Evenepoel P, Iles J, Sun Y, Ure\u00f1a-Torres P, Bushinsky DA (2019) Etelcalcetide is effective at all levels of severity of secondary hyperparathyroidism in hemodialysis patients. Kidney Int Rep 4:987\u2013994","journal-title":"Kidney Int Rep"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01158-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-020-01158-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01158-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T05:46:22Z","timestamp":1634017582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-020-01158-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1158"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01158-2","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"21 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AF, AI, KH, MT, YS, and HY are employees of Ono Pharmaceutical Co., Ltd.; YI, ME, and MI are on the speaker bureau for Ono Pharmaceutical Co., Ltd.; IK, TH, DM, and NH: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}